Authors:
Wierzbicki, AS
Hardman, TC
Cheung, J
Patel, M
Smallberger, S
Lumb, PJ
Lant, AF
Citation: As. Wierzbicki et al., Relation between sodium-lithium countertransport and hypertriglyceridemia in type V hyperlipidemia, AM J HYPERT, 14(1), 2001, pp. 32-37
Authors:
Moore, KHP
Cass, LM
Dallow, N
Hardman, TC
Jones, A
Boyce, M
Prince, WT
Citation: Khp. Moore et al., Pharmacokinetics and tolerability of GW420867X, a nonnucleoside reverse transcriptase inhibitor, following single escalating doses in healthy male volunteers, J CLIN PHAR, 41(10), 2001, pp. 1098-1105
Authors:
Moore, KHP
Cass, LM
Dallow, N
Hardman, TC
Jones, A
Boyce, M
Prince, WT
Citation: Khp. Moore et al., Pharmacokinetics and safety of escalating single and repeat oral doses of GW420867X, a novel non-nucleoside reverse transcriptase inhibitor, EUR J CL PH, 56(11), 2001, pp. 805-811
Authors:
Wierzbicki, AS
Hardman, TC
Cheung, J
Lambert-Hammill, M
Patel, S
Morrish, Z
Lumb, PJ
Lant, AF
Citation: As. Wierzbicki et al., Effects of lipids in patients with familial hypercholesterolaemia on the kinetics of the sodium-lithium countertransporter, J HUM HYPER, 14(9), 2000, pp. 561-565
Authors:
Hardman, TC
Dubrey, SW
Soni, S
Clifford, R
Chalkley, S
Wierzbicki, AS
Citation: Tc. Hardman et al., Urinary retinol-binding protein (RBP) excretion and erythrocyte sodium-lithium countertransport (SLC) activity in a cohort of healthy normotensive subjects, J HUM HYPER, 13(12), 1999, pp. 871-873
Citation: Tc. Hardman et al., Enhanced activity of sodium-lithium countertransport in patients with cardiac syndrome X: A potential link between cardiac and metabolic syndrome X, J AM COL C, 34(3), 1999, pp. 955-956